{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T23:10:43Z","timestamp":1784589043604,"version":"3.55.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T00:00:00Z","timestamp":1705363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T00:00:00Z","timestamp":1705363200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Herzzentrum G\u00f6ttingen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Intervent Radiol"],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>To investigate the long-term results of the Eluvia drug-eluting stent (DES) implantation for femoropopliteal arterial disease, including the \u2018halo\u2019 phenomenon. Long-term data of DES is scarce. A focal reaction (\u2018halo\u2019) following Eluvia DES deployment has been described. However, the long-term clinical impact of this phenomenon remains unclear.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This prospective, non-randomized, single-arm study included 130 consecutive patients treated with an Eluvia DES for symptomatic femoropopliteal disease between March 2016 and December 2018. Clinical outcomes and imaging were assessed after 6\u00a0months and annually thereafter for up to 5\u00a0years. The primary outcome measure was primary patency. Secondary outcomes were freedom from clinically driven target lesion revascularization (CD-TLR), freedom from major amputation, overall survival and amputation-free survival rates.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The primary patency was 65% at 5\u00a0years. The freedom from CD-TLR and from major amputation at 5\u00a0years was 79 and 96%, respectively. The overall survival and amputation-free survival rates were 88 and 83% at 60\u00a0months, respectively. Out of the 27 patients with a halo sign, two showed an increased (7.4%) and 6 (22.2%) a decreased diameter. In 19 cases (70.4%), the diameter remained unchanged at the latest follow-up. The presence of the \u2018halo\u2019 sign was associated with increased primary patency (87% versus 59%, HR: 2.48, 95%CI 1.19\u20135.16, <jats:italic>P<\/jats:italic>\u2009=\u2009.015).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The presented patient cohort treated with the Eluvia DES for femoropopliteal artery lesions indicates durable efficacy and a good safety profile regardless of the halo phenomenon. The results need to be confirmed in a larger patient cohort.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Level of Evidence III<\/jats:title>\n                <jats:p>Non-randomized controlled cohort\/follow-up study.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Graphical Abstract<\/jats:title>\n                \n              <\/jats:sec>","DOI":"10.1007\/s00270-023-03652-2","type":"journal-article","created":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T18:01:56Z","timestamp":1705428116000},"page":"177-185","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Treatment of Femoropopliteal Artery Disease with Polymer-Coated Drug-Eluting Stent: 5-Year Results of a Prospective, Non-Randomized Study Including the Halo Phenomenon"],"prefix":"10.1007","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9938-2947","authenticated-orcid":false,"given":"Giovanni Federico","family":"Torsello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Stavroulakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodosios","family":"Bisdas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yamel","family":"Cardona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin","family":"Wichmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni Battista","family":"Torsello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,16]]},"reference":[{"key":"3652_CR1","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1016\/j.jcin.2016.09.039","volume":"24","author":"T Bisdas","year":"2016","unstructured":"Bisdas T, Borowski M, Stavroulakis K, Torsello G. CRITISCH Collaborators Endovascular. therapy versus bypass surgery as first-line treatment strategies for critical limb ischemia: results of the interim analysis of the CRITISCH registry. J Am Coll Cardiol Intv. 2016;24:2557\u201365.","journal-title":"J Am Coll Cardiol Intv"},{"key":"3652_CR2","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1056\/NEJMoa2207899","volume":"25","author":"A Farber","year":"2022","unstructured":"Farber A, Menard MT, Conte MS, et al. Surgery or endovascular therapy for chronic limb-threatening ischemia. N Engl J Med. 2022;25:2305\u201316.","journal-title":"N Engl J Med"},{"key":"3652_CR3","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1093\/eurheartj\/ehv204","volume":"14","author":"B Cortese","year":"2016","unstructured":"Cortese B, Granada JF, Scheller B, et al. Drug-coated balloon treatment for lower extremity vascular disease intervention: an international positioning document. Eur Heart J. 2016;14:1096\u2013103.","journal-title":"Eur Heart J"},{"key":"3652_CR4","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.jcin.2021.01.026","volume":"6","author":"K Stavroulakis","year":"2021","unstructured":"Stavroulakis K, Torsello G, Bosiers M, Argyriou A, Tsilimparis N, Bisdas T. 2-Year outcomes of the eluvia drug-eluting stent for the treatment of complex femoropopliteal lesions. J Am Coll Cardiol Intv. 2021;6:692\u2013701.","journal-title":"J Am Coll Cardiol Intv"},{"key":"3652_CR5","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1161\/CIRCULATIONAHA.122.059606","volume":"21","author":"Y Gou\u00ebffic","year":"2022","unstructured":"Gou\u00ebffic Y, Torsello G, Zeller T, et al. Efficacy of a drug-eluting stent versus bare metal stents for symptomatic femoropopliteal peripheral artery disease: primary results of the EMINENT randomized trial. Circ. 2022;21:1564\u201376.","journal-title":"Circ"},{"key":"3652_CR6","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1007\/s00270-020-02693-1","volume":"44","author":"S M\u00fcller-H\u00fclsbeck","year":"2021","unstructured":"M\u00fcller-H\u00fclsbeck S, Benko A, Soga Y, et al. Two-Year efficacy and safety results from the IMPERIAL randomized study of the eluvia polymer-coated drug-eluting stent and the zilver PTX polymer-free drug-coated stent. Cardiovasc Intervent Radiol. 2021;44:368\u201375.","journal-title":"Cardiovasc Intervent Radiol"},{"key":"3652_CR7","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s42155-021-00245-3","volume":"1","author":"T Tsujimura","year":"2021","unstructured":"Tsujimura T, Iida O, Asai M, et al. Aneurysmal degeneration of fluoropolymer-coated paclitaxel-eluting stent in the superficial femoral artery: a rising concern. CVIR Endovasc. 2021;1:56.","journal-title":"CVIR Endovasc"},{"key":"3652_CR8","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/j.jcin.2018.03.046","volume":"11","author":"T Bisdas","year":"2018","unstructured":"Bisdas T, Beropoulis E, Argyriou A, Torsello G, Stavroulakis K. 1-year all-comers analysis of the eluvia drug-eluting stent for long femoropopliteal lesions after suboptimal angioplasty. J Am Coll Cardiol Intv. 2018;11:957\u201366.","journal-title":"J Am Coll Cardiol Intv"},{"key":"3652_CR9","first-page":"E212","volume":"6","author":"KJ Rocha-Singh","year":"2014","unstructured":"Rocha-Singh KJ, Zeller T, Jaff MR. Peripheral arterial calcification: prevalence, mechanism, detection, and clinical implications. Catheter Cardiovasc Interv. 2014;6:E212\u201320.","journal-title":"Catheter Cardiovasc Interv"},{"key":"3652_CR10","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.jcin.2022.01.019","volume":"6","author":"O Iida","year":"2022","unstructured":"Iida O, Takahara M, Soga Y, et al. 1-Year outcomes of fluoropolymer-based drug- eluting stent in femoropopliteal practice: predictors of restenosis and aneurysmal degeneration. J Am Coll Cardiol Intv. 2022;6:630\u20138.","journal-title":"J Am Coll Cardiol Intv"},{"key":"3652_CR11","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1177\/1358863X20987894","volume":"3","author":"S Kum","year":"2021","unstructured":"Kum S, Ipema J, Huizing E, et al. Outcomes of the paclitaxel-eluting Eluvia stent for long femoropopliteal lesions in Asian patients with predominantly chronic limb- threatening ischemia. Vasc Med. 2021;3:267\u201372.","journal-title":"Vasc Med"},{"key":"3652_CR12","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1097\/MCA.0000000000000996","volume":"7","author":"K Ueno","year":"2021","unstructured":"Ueno K, Morita N, Kojima Y, et al. Acute diffuse thickening like \u201chalo\u201d of the coronary tunica adventitia after rotational atherectomy. Coron Artery Dis. 2021;7:665\u20137.","journal-title":"Coron Artery Dis"},{"key":"3652_CR13","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.jvir.2021.02.014","volume":"6","author":"A Sakamoto","year":"2021","unstructured":"Sakamoto A, Torii S, Jinnouchi H, et al. Vascular response of a polymer-free paclitaxel-coated stent (Zilver PTX) versus a polymer-coated paclitaxel-eluting stent (Eluvia) in healthy swine femoropopliteal arteries. J Vasc Interv Radiol. 2021;6:792\u2013801.","journal-title":"J Vasc Interv Radiol"},{"key":"3652_CR14","doi-asserted-by":"publisher","DOI":"10.1177\/2050313X211014519","author":"Y Soga","year":"2021","unstructured":"Soga Y, Ando K. \u201cLow Echoic Area\u201d around stent after bare and drug-coated stenting or stent graft placement for superficial femoral artery disease. SAGE Open Med Case Rep. 2021. https:\/\/doi.org\/10.1177\/2050313X211014519.","journal-title":"SAGE Open Med Case Rep"},{"key":"3652_CR15","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1177\/1526602816683933","volume":"2","author":"K Stavroulakis","year":"2017","unstructured":"Stavroulakis K, Schwindt A, Torsello G, et al. Directional atherectomy with antirestenotic therapy vs drug-coated balloon angioplasty alone for isolated popliteal artery lesions. J Endovasc Ther. 2017;2:181\u20138.","journal-title":"J Endovasc Ther"}],"container-title":["CardioVascular and Interventional Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00270-023-03652-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00270-023-03652-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00270-023-03652-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,5]],"date-time":"2024-02-05T16:04:12Z","timestamp":1707149052000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00270-023-03652-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,16]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["3652"],"URL":"https:\/\/doi.org\/10.1007\/s00270-023-03652-2","relation":{},"ISSN":["0174-1551","1432-086X"],"issn-type":[{"value":"0174-1551","type":"print"},{"value":"1432-086X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,16]]},"assertion":[{"value":"15 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"GFT consulting for Boston Scientific, Penumbra and Terumo, received Honoraria from Boston Scientific, Philips and Penumbra and Research grants from WL Gore and Berlin Institute of Health. KS consulting for Phillips, Shockwave, Terumo, Boston Scientific, received Honoraria from Medtronic, Abbott, Cook, Bentley and Biotronic and Research grants from Boston Scientific. TB: consulting for BD, Boston Scientific, Cook Medical, Medtronic. YC and KW done none. GBT done research funding from WL Gore and speaker honoraria from Penumbra.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Institutional Review Board (IRB) approval was obtained.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}},{"value":"Consent for publication was obtained for every individual person\u2019s data included in the study.\u201d","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}}]}}